Literature DB >> 10804015

In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene.

J E Onyia1, R R Miles, X Yang, D L Halladay, J Hale, A Glasebrook, D McClure, G Seno, L Churgay, S Chandrasekhar, T J Martin.   

Abstract

Osteoprotegerin (OPG) is a potent inhibitor of osteoclast formation and function. To elucidate how OPG is regulated in bone, we examined (1) the expression and localization of OPG protein in bone tissue, (2) the effect of human parathyroid hormone 1-38 (hPTH 1-38) on OPG messenger RNA (mRNA) levels in rat femur metaphyseal and diaphyseal bone, and (3) the effect of hPTH(1-38) on expression of OPG mRNA in cultured osteoblast-like cells derived from the metaphysis and diaphysis, and in ROS 17/2.8 osteosarcoma cells. Because PTH has been shown to stimulate osteoblast activity via the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signal transduction pathway we also investigated whether PTH action on OPG in vivo is dependent on activation of cAMP/PKA pathway. Immunohistochemistry was used to evaluate OPG protein expression and Northern blot hybridization was used to analyze OPG mRNA expression both in vivo and in vitro. Immunohistochemistry of OPG protein expression in the rat distal femur metaphysis revealed that it was localized predominantly in preosteoblasts, osteoblasts, lining cells, and the osteoid layer, with occasional immunoreactivity in osteocytes and cells of the bone marrow. Subcutaneous (sc) administration of a single injection of hPTH(1-38) at 80 microg/kg induced a rapid and transient decrease in OPG mRNA expression in both metaphyseal and diaphyseal bone. The decrease in OPG message was evident by 1 h and mRNA levels returned to baseline after 3 h. PTH analog PTH(1-31), which stimulates intracellular cAMP accumulation, inhibited OPG expression, whereas PTH analogs (3-34 and 7-34) that do not stimulate cAMP production had no effect on expression. In contrast to PTH, prostaglandin E2 (PGE2) had no effect on OPG mRNA expression in vivo in the metaphyseal bone cells, under conditions in which PGE2 does promote expression of the c-fos gene. The in vivo effects of hPTH(1-38) on OPG mRNA were confirmed in isolated primary osteoblast cultures derived from either metaphyseal or diaphyseal bone as well as in ROS 17/2.8 osteosarcoma cells. We propose that the rapid and transient decrease in OPG expression may initiate a cascade of events resulting in the differentiation of osteoclast progenitor. Such a spatially and temporally programmed effect of PTH might contribute to bone turnover.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804015     DOI: 10.1359/jbmr.2000.15.5.863

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  19 in total

1.  Intermittent PTH(1-34) signals through protein kinase A to regulate osteoprotegerin production in human periodontal ligament cells in vitro.

Authors:  Dominik Kraus; Andreas Jäger; Nuersailike Abuduwali; James Deschner; Stefan Lossdörfer
Journal:  Clin Oral Investig       Date:  2011-03-29       Impact factor: 3.573

Review 2.  Heterotrimeric G proteins in the control of parathyroid hormone actions.

Authors:  Murat Bastepe; Serap Turan; Qing He
Journal:  J Mol Endocrinol       Date:  2017-05       Impact factor: 5.098

Review 3.  Osteocyte control of osteoclastogenesis.

Authors:  Charles A O'Brien; Tomoki Nakashima; Hiroshi Takayanagi
Journal:  Bone       Date:  2012-08-23       Impact factor: 4.398

4.  Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice.

Authors:  Yasunori Sakakura; Eichi Tsuruga; Kazuharu Irie; Yoichiro Hosokawa; Hiroaki Nakamura; Toshihiko Yajima
Journal:  J Anat       Date:  2005-10       Impact factor: 2.610

Review 5.  Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders.

Authors:  Natalia Carrillo-López; Laura Martínez-Arias; Jorge B Cannata-Andía; Manuel Naves-Díaz; Sara Panizo; Sara Fernández-Villabrille; María Piedad Ruiz-Torres; Adriana Dusso
Journal:  Calcif Tissue Int       Date:  2021-02-13       Impact factor: 4.333

6.  Osteoprotegerin and bone mineral density in hemodialysis patients.

Authors:  A Nakashima; N Yorioka; S Doi; N Takasugi; K Shigemoto; N Kohno
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

7.  Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.

Authors:  Ina Kramer; Christine Halleux; Hansjoerg Keller; Marco Pegurri; Jonathan H Gooi; Patricia Brander Weber; Jian Q Feng; Lynda F Bonewald; Michaela Kneissel
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

Review 8.  Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression.

Authors:  Sutada Lotinun; Jean D Sibonga; Russell T Turner
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

9.  Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat.

Authors:  Giuliana Silvestrini; Paola Ballanti; Francesca Patacchioli; Martina Leopizzi; Novella Gualtieri; Paola Monnazzi; Elisa Tremante; Daniela Sardella; Ermanno Bonucci
Journal:  J Mol Histol       Date:  2005-02       Impact factor: 2.611

10.  Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis.

Authors:  Luca Pietrogrande
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.